{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:21:34Z","timestamp":1790623294166,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006451","name":"Hospices Civils de Lyon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006451","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Elexacaftor\/tezacaftor\/ivacaftor (ETI) is a new cystic fibrosis transmembrane conductance regulator (CFTR) modulator that has transformed the respiratory prognosis of people with cystic fibrosis (pwCF). However, its impact on other organs such as the kidneys, where CFTR is expressed, remains unclear. Since pwCF are risk of both kidney disease and urolithiasis, we aimed to study the potential effects of ETI on renal function, volume status, and risk factors for urolithiasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This prospective, observational, single-center, before\u2013after cohort study, involved adult pwCF eligible for ETI. The changes in plasma and urinary profiles were assessed by comparing renal function (using 2021 CKD-EPIcreatinine and 2021 CKD-EPIcreatinine-cystatin C formulas), volume status (using aldosterone\/renin ratio and blood pressure), and risk factors for urolithiasis, at the time of ETI introduction (M0) and 7 months after (M7).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Nineteen pwCF were included. No significant change in renal function was observed between M0 and M7 (2021 CKD-EPIcreatinine: 105.5\u00a0ml\/min\/1.73 m\u00b2 at M0 vs. 103.3\u00a0ml\/min\/1.73 m\u00b2 at M7; P\u00a0=\u00a0.17). There was a significant reduction in aldosterone level (370.3\u00a0pmol\/l at M0 vs. 232.4\u00a0pmol\/l at M7; P\u00a0=\u00a0.02) and aldosterone\/renin ratio (33.6 at M0 vs. 21.8 at M7; P\u00a0=\u00a0.03). Among the risk factors for urolithiasis, a significant reduction in magnesuria level was found (4.6\u00a0mmol\/d at M0 vs. 3.8\u00a0mmol\/d at M7; P\u00a0=\u00a0.01).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These findings suggest that ETI seem to have no short-term impact on the renal function of adult pwCF and appears to correct secondary hyperaldosteronism due to excessive sweat losses. Further investigations are needed to determine the potential impact of decreased magnesuria observed under ETI therapy on the risk of urolithiasis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfae256","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T01:41:30Z","timestamp":1724809290000},"source":"Crossref","is-referenced-by-count":10,"title":["Kidney effects of triple CFTR modulator therapy in people with cystic fibrosis"],"prefix":"10.1093","volume":"17","author":[{"given":"Pierre","family":"Gabai","sequence":"first","affiliation":[{"name":"Service de N\u00e9phrologie, Hospices Civils de Lyon, H\u00f4pital Lyon Sud , 165 Chemin du Grand Revoyet, Pierre-B\u00e9nite , Rh\u00f4ne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8609-3572","authenticated-orcid":false,"given":"Etienne","family":"Novel-Catin","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie, Hospices Civils de Lyon, H\u00f4pital Lyon Sud , 165 Chemin du Grand Revoyet, Pierre-B\u00e9nite , Rh\u00f4ne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quitterie","family":"Reynaud","sequence":"additional","affiliation":[{"name":"Centre de Ressource et de Comp\u00e9tences de la mucoviscidose, Service de m\u00e9decine Interne et de Pathologie Vasculaire, Hospices Civils de Lyon, H\u00f4pital Lyon Sud , 165 Chemin du Grand Revoyet, Pierre-B\u00e9nite , Rh\u00f4ne,","place":["France"]},{"name":"ERN-Lung Cystic Fibrosis Network , Frankfurt , Frankfurt Region,","place":["Germany"]},{"name":"RESearch on HealthcAre PErformance (RESHAPE), INSERM U1290, Claude Bernard Lyon 1 University , 8 Avenue Rockfeller, Lyon Cedex 08, Rh\u00f4ne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00eble","family":"Nove-Josserand","sequence":"additional","affiliation":[{"name":"Centre de Ressource et de Comp\u00e9tences de la mucoviscidose, Service de m\u00e9decine Interne et de Pathologie Vasculaire, Hospices Civils de Lyon, H\u00f4pital Lyon Sud , 165 Chemin du Grand Revoyet, Pierre-B\u00e9nite , Rh\u00f4ne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenne","family":"Pelletier","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie, Hospices Civils de Lyon, H\u00f4pital Lyon Sud , 165 Chemin du Grand Revoyet, Pierre-B\u00e9nite , Rh\u00f4ne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9707-7199","authenticated-orcid":false,"given":"Denis","family":"Fouque","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie, Hospices Civils de Lyon, H\u00f4pital Lyon Sud , 165 Chemin du Grand Revoyet, Pierre-B\u00e9nite , Rh\u00f4ne,","place":["France"]},{"name":"CarMeN Laboratory, INSERM, INRAE, Claude Bernard Lyon 1 University , Pierre-B\u00e9nite , Rh\u00f4ne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5076-2420","authenticated-orcid":false,"given":"Laetitia","family":"Koppe","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie, Hospices Civils de Lyon, H\u00f4pital Lyon Sud , 165 Chemin du Grand Revoyet, Pierre-B\u00e9nite , Rh\u00f4ne,","place":["France"]},{"name":"CarMeN Laboratory, INSERM, INRAE, Claude Bernard Lyon 1 University , Pierre-B\u00e9nite , Rh\u00f4ne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Durieu","sequence":"additional","affiliation":[{"name":"Centre de Ressource et de Comp\u00e9tences de la mucoviscidose, Service de m\u00e9decine Interne et de Pathologie Vasculaire, Hospices Civils de Lyon, H\u00f4pital Lyon Sud , 165 Chemin du Grand Revoyet, Pierre-B\u00e9nite , Rh\u00f4ne,","place":["France"]},{"name":"ERN-Lung Cystic Fibrosis Network , Frankfurt , Frankfurt Region,","place":["Germany"]},{"name":"RESearch on HealthcAre PErformance (RESHAPE), INSERM U1290, Claude Bernard Lyon 1 University , 8 Avenue Rockfeller, Lyon Cedex 08, Rh\u00f4ne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"2024100108205526700_bib1","article-title":"Registre fran\u00e7ais de la mucoviscidose\u2014Bilan des donn\u00e9es 2022"},{"key":"2024100108205526700_bib2","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1126\/science.2570460","article-title":"Identification of the cystic fibrosis gene: genetic analysis","volume":"245","author":"Kerem","year":"1989","journal-title":"Science"},{"key":"2024100108205526700_bib3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0140-6736(08)61162-9","article-title":"Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis","volume":"372","author":"Quinton","year":"2008","journal-title":"Lancet"},{"key":"2024100108205526700_bib4","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"2024100108205526700_bib5","doi-asserted-by":"publisher","first-page":"9262","DOI":"10.1073\/pnas.88.20.9262","article-title":"Immunocytochemical localization of the cystic fibrosis gene product CFTR","volume":"88","author":"Crawford","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024100108205526700_bib6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/ndt\/gfy084","article-title":"Aminoglycoside exposure and renal function before lung transplantation in adult cystic fibrosis patients","volume":"34","author":"Novel-Catin","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2024100108205526700_bib7","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0022-5347(01)66126-3","article-title":"Urolithiasis and cystic fibrosis","volume":"155","author":"Matthews","year":"1996","journal-title":"J Urol"},{"key":"2024100108205526700_bib8","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S0022-5347(01)69068-2","article-title":"Metabolic risk factors for stone formation in patients with cystic fibrosis","volume":"167","author":"Perez-Brayfield","year":"2002","journal-title":"J Urol"},{"key":"2024100108205526700_bib9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s004670050452","article-title":"Urinary excretion substances in patients with cystic fibrosis: risk of urolithiasis?","volume":"12","author":"Hoppe","year":"1998","journal-title":"Pediatr Nephrol"},{"key":"2024100108205526700_bib10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/BF01295647","article-title":"Increased risk of nephrolithiasis in patients with steatorrhea","volume":"27","author":"Dharmsathaphorn","year":"1982","journal-title":"Dig Dis Sci"},{"key":"2024100108205526700_bib11","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/S0140-6736(98)03038-4","article-title":"Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria","volume":"352","author":"Sidhu","year":"1998","journal-title":"Lancet"},{"key":"2024100108205526700_bib12","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s00345-023-04277-3","article-title":"Role, importance and assessment of dietary habits in urolithiasis patient","volume":"41","author":"Yitgin","year":"2023","journal-title":"World J Urol"},{"key":"2024100108205526700_bib13","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.healun.2014.08.004","article-title":"International Society for Heart and Lung Transplantation. The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report\u20142014; focus theme: retransplantation","volume":"33","author":"Yusen","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"2024100108205526700_bib14","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.chest.2017.01.019","article-title":"Heterogeneity in survival in adult patients with cystic fibrosis with FEV1 &lt; 30% of predicted in the United States","volume":"151","author":"Ramos","year":"2017","journal-title":"Chest"},{"key":"2024100108205526700_bib15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1055\/s-0035-1547347","article-title":"Lung transplantation for cystic fibrosis: results, indications, complications, and controversies","volume":"36","author":"Lynch","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"2024100108205526700_bib16","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1093\/ckj\/sfaa053","article-title":"Measurement of glomerular filtration rate in lung transplant recipients highlights a dramatic loss of renal function after transplantation","volume":"13","author":"Florens","year":"2020","journal-title":"Clin Kidney J"},{"key":"2024100108205526700_bib17","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3389\/fphar.2016.00275","article-title":"CFTR modulators: shedding light on precision medicine for cystic fibrosis","volume":"7","author":"Lopes-Pacheco","year":"2016  5","journal-title":"Front Pharmacol"},{"key":"2024100108205526700_bib18","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s40265-019-01233-7","article-title":"Elexacaftor\/Ivacaftor\/Tezacaftor: first approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"2024100108205526700_bib19","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2024100108205526700_bib20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024100108205526700_bib21","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"VX18-445-104 study group. Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"2024100108205526700_bib22","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"Chronic kidney disease epidemiology collaboration. New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2024100108205526700_bib23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"2024100108205526700_bib24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2024100108205526700_bib25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jcf.2006.05.004","article-title":"Comparison of methods of assessment of renal function in cystic fibrosis (CF) patients","volume":"6","author":"Al-Aloul","year":"2007","journal-title":"J Cyst Fibros"},{"key":"2024100108205526700_bib26","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1203\/00006450-197111000-00007","article-title":"The Renin-angiotensin-aldosterone system in patients with cystic fibrosis of the pancreas","volume":"5","author":"Simopoulos","year":"1971","journal-title":"Pediatr Res"},{"key":"2024100108205526700_bib27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/MED.0b013e3283391989","article-title":"Aldosterone and inflammation","volume":"17","author":"Gilbert","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2024100108205526700_bib28","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.jcf.2022.12.017","article-title":"CFTR-beyond the airways: recent findings on the role of the CFTR channel in the pancreas, the intestine and the kidneys","volume":"22","author":"Hegyi","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024100108205526700_bib29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.advnut.2023.03.002","article-title":"Kidney stone prevention","volume":"14","author":"Peerapen","year":"2023","journal-title":"Adv Nutr"},{"key":"2024100108205526700_bib30","doi-asserted-by":"publisher","first-page":"904203","DOI":"10.3389\/fphys.2022.904203","article-title":"The role of mechanosensitive ion channels in the gastrointestinal tract","volume":"13","author":"Yang","year":"2022","journal-title":"Front Physiol"},{"key":"2024100108205526700_bib31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ceca.2019.05.007","article-title":"Focus on TRP channels in cystic fibrosis","volume":"81","author":"Grebert","year":"2019","journal-title":"Cell Calcium"},{"key":"2024100108205526700_bib32","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1007\/s00018-016-2149-6","article-title":"Function and regulation of TRPM7, as well as intracellular magnesium content, are altered in cells expressing \u0394F508-CFTR and G551D-CFTR","volume":"73","author":"Huguet","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"2024100108205526700_bib33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/ppul.23356","article-title":"Magnesium in cystic fibrosis\u2014systematic review of the literature","volume":"51","author":"Santi","year":"2016","journal-title":"Pediatr Pulmonol"},{"key":"2024100108205526700_bib34","doi-asserted-by":"publisher","first-page":"1019028","DOI":"10.3389\/fphys.2022.1019028","article-title":"Ion channels as a therapeutic target for renal fibrosis","volume":"13","author":"Yan","year":"2022","journal-title":"Front Physiol"},{"key":"2024100108205526700_bib35","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jcf.2023.08.002","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis","volume":"22","author":"Hergenroeder","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024100108205526700_bib36","doi-asserted-by":"publisher","first-page":"100690","DOI":"10.1016\/j.lanepe.2023.100690","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg Health Eur"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae256\/58937144\/sfae256.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/10\/sfae256\/59465396\/sfae256.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/10\/sfae256\/59465396\/sfae256.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T08:21:31Z","timestamp":1727770891000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae256\/7742831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae256","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,8,27]]},"article-number":"sfae256"}}